secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-08-06T12:05:22+00:00
Accession:  0001193125-26-336843
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q2 2026 net loss $18.0M; cash $153.4M; refinances debt facility
----------------------------------------------------------------------------

- GAAP net loss of $18.0M ($0.13/share) vs $25.9M ($0.49/share) in Q2 2025; non-GAAP net loss $14.3M.
- Cash, equivalents and investments $153.4M; sufficient to fund operations through H1 2028.
- Refinanced $10M debt with HSBC Ventures; can draw up to additional $20M through June 2028; total facility up to $50M.
- Appointed Scott Garland as Chairman and Michael Listgarten as General Counsel.
- ASPEN-09-Breast Phase 2 topline data from 80 patients expected mid-2027; ALX2004 safety data expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/0001193125-26-336843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526336843/alxo-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer